A prominent Indian-American cancer and gene therapy scientist in the US has been placed on administrative leave following allegations of "inappropriate conduct" against him.
Inder Verma, a cancer and gene therapy scientist at the prestigious Salk Institute for Biological Studies in California, has been placed on administrative leave, pending the outcome of the investigation into the allegations against him.
The institute did not give any reason for suspending 70-year-old Verma, who is considered as one of the world's leading authorities on gene therapy and cancer.
The institute has hired The Rose Group, a San Diegobased international employment law and consulting firm, to investigate allegations, not yet made public, that were reported to the institute in February.
"Recently, the institute became aware of allegations concerning Inder Verma. Consistent with Salk's policies governing workplace conduct, the institute has undertaken a formal investigation that is being led by an independent outside party," Dan Lewis, chairman of the Salk Institute for Biological Studies said in a statement.
Verma has been placed on administrative leave, pending the outcome of the investigation. He will not be performing scientific or administrative roles on behalf of the institute during this period," he said, without referring to the nature of the investigation.
The action against Verma comes nearly four months after he was placed on temporary leave as editor of the Proceedings of the National Academy of Sciences, a prestigious scientific journal.
The allegations of inappropriate conduct against Verma were first reported by Science magazine, according to which last summer, three female Salk senior scientists sued the institute for gender discrimination calling it an "old boys club" that had systematically impeded their careers because they were women. The lawsuits are set to go to trial next December.
Verma told the San Diego Union-Tribune that the leave had stemmed from the lawsuits that Salk professors filed against the Institute in July.
Verma, 70, who is also on the boards of several Indian scientific institutes, has denied the allegations.
"I have never used my position at the Salk Institute to take advantage of others. I have also never engaged in any sort of intimate relationship with anyone affiliated with the Salk Institute, he said in a statement to Science through his attorney.
"I have never inappropriately touched, nor have I made any sexually charged comments, to anyone affiliated with the Salk Institute. I have never allowed any offensive or sexually charged conversations, jokes, material, etc. to occur at the Salk Institute, said Verma who earned his MSc in Biochemistry from the Lucknow University.
Denying misconduct allegations to the Union-Tribune, Verma said, "I believe that it is inappropriate for an individual in a position of authority to engage in any intimate relationship with a direct report or to use that position of authority to take advantage of others."
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
